Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol

Peer Review reports

Original Submission
30 May 2016	Submitted	Original manuscript
15 Dec 2016	Author responded	Author comments - Masahiro Sekimizu
Resubmission - Version 2
15 Dec 2016	Submitted	Manuscript version 2
3 Jan 2017	Reviewed	Reviewer Report - Dj Murry
22 Mar 2017	Reviewed	Reviewer Report - Matthew Barth
25 Jul 2017	Author responded	Author comments - Masahiro Sekimizu
Resubmission - Version 3
25 Jul 2017	Submitted	Manuscript version 3
22 Nov 2017	Author responded	Author comments - Masahiro Sekimizu
Resubmission - Version 4
22 Nov 2017	Submitted	Manuscript version 4
Publishing
24 Jan 2018	Editorially accepted
1 Feb 2018	Article published	10.1186/s12885-018-4042-1

Back to article page